SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
Capital infusion to accelerate Earendil’s R&D platform
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
It promises fewer injections for vision loss patients
Call it a major breakthrough for diagnostic imaging
The company plans to submit the vaccine for regulatory review
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
